Mr. Michael Frank reports

REVIVE THERAPEUTICS OUTLINES STRATEGY TO BUILD A BIODEFENCE AND PANDEMIC PREPAREDNESS THERAPEUTICS PORTFOLIO

Revive Therapeutics Ltd. today outlined its strategy to build a focused medical-countermeasure portfolio led by bucillamine.

Chemical threats, biological events and future pandemics can emerge faster than new medicines can be developed. Governments therefore need potential medical countermeasures to be researched, validated and positioned for deployment before an emergency occurs. Revive's objective is clear: advance therapeutics that meet that preparedness need, beginning with bucillamine and supported over time by carefully selected complementary products.

The strategy follows Revive's Aug. 12, 2026, announcement of positive results from a DRDC research study evaluating bucillamine in an established animal model of nerve-agent exposure. In that study, bucillamine appeared comparable to N-acetylcysteine (NAC) in preserving the measured hippocampal GABA receptor postsynaptic density end point. No pulmonary hemorrhage was observed in the bucillamine-treated group, whereas pulmonary hemorrhage was observed in the NAC-treated group.

Michael Frank, chief executive officer of Revive, commented: "The DRDC results give Revive an important starting point. Our plan is straightforward: confirm what bucillamine may be able to do, pursue government-supported opportunities in Canada, the United States and allied markets, strengthen the intellectual property, and add complementary assets only where they improve the portfolio. If successfully executed, we believe this strategy could create multiple paths to long-term growth."

The potential of bucillamine for medical countermeasures

Medical countermeasures are different from traditional prescription drugs. The principal customers may include governments, defence organizations and public-health agencies seeking products that can be developed, procured, deployed and, where appropriate, stockpiled for emergencies. Potential value can therefore be created through more than conventional commercial sales, including government-funded research, non-dilutive development support, strategic licensing, procurement contracts and stockpile replenishment.

Revive believes bucillamine may offer a practical foundation for this strategy.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness. The company is advancing bucillamine across potential medical-countermeasure and infectious-disease applications and is evaluating complementary portfolio opportunities.

We seek Safe Harbor.